Utility of the BTA stat test kit for bladder cancer screening

Diagnostic Cytopathology

Volumn 21, Issue 1, 1999, Pages 27-29

  Nasuti, Joseph F ^a,b   Gomella, Leonard G ^a   Ismial, Mohammed ^a   Bibbo, Marluce ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

BTA stat test; Transitional cell carcinoma; Voided urine cytology

Indexed keywords

TUMOR ANTIGEN;

ARTICLE; BLADDER BIOPSY; BLADDER CANCER; CANCER CYTODIAGNOSIS; CANCER SCREENING; CONTROLLED STUDY; CYSTOSCOPY; DEVICE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; URINE CYTOLOGY;

ANTIGENS, NEOPLASM; BLOOD PROTEINS; CARCINOMA, TRANSITIONAL CELL; COMPLEMENT FACTOR H; EVALUATION STUDIES; FOLLOW-UP STUDIES; HUMANS; MASS SCREENING; NEOPLASM INVASIVENESS; REAGENT KITS, DIAGNOSTIC; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0033021891     PISSN: 87551039     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0339(199907)21:1<27::AID-DC8>3.0.CO;2-8     Document Type: Article

References (16)

1. Holmquest ND. Detection of urinary tract cancer in urinalysis specimens in an outpatient population. Am J Clin Pathol 1988;89:499-504.
2. El-Bolkainy MN. Cytology of bladder carcinoma. J Urol 1980;124:20-22.
3. Jacobs R. A review of the effectiveness of urinary cytology as a screening technique for occupational bladder cancer. J Soc Occup Med 1987;37:24-26.
4. Hinyokika K. Etiology of asymptomatic microhematuria in adults. Acta Urol Jap 1993;39:413-417.
5. Wiener HG, Voorjs GP, Vant Hof Grootenboer B. Accuracy of urine cytology in the diagnoses of primary and recurrent bladder cancer. Acta Cytol 1993;37:163-169.
6. Koss LG, Deitch D, Ramathan R, Sherman AB. Diagnostic value of cytopathology of voided urine. Acta Cytol 1985;29:810-816.
7. Kern WH. The diagnostic accuracy of sputum and urine cytology. Acta Cytol 1988;32:651-654.
8. Husermann M., Sommer E, Blumberg A. Urinary cytology in tumors of the urinary tract. J Suisse Med 1979;109:309.
9. Kern WH. Urinary tract. In: Bibbo M, editor. Comprehensive cytopathology. Second edition. Philadelphia: WB Saunders, 1997. p 474-475.
10. Margulies LM, Hoyhtya M, Evans C, Stracke ML, Liotta LA, Stetler-Stevenson WG. Urinary type IV collagenase: elevated levels are associated with bladder transitional cell carcinoma. Cancer Epidemiol. Biomarkers Prev 1992;6:467-474.
11. Hughes JH, Rodriquez-Villanuevas J, Kidd L, Lucio L, Desai J, Katz RL. Urinary nuclear matrix protein 22 (NMP22): a diagnostic adjunct to urine cytology for the detection of recurrent transitional cell carcinoma of the bladder. Acta Cytol 1997;41:7
12. Kinders R, Jones T, Root R, et al. Human bladder tumor antigen is a member of the RCA (regulators of complement activation) gene family. J Urol 1997;4:28
13. Kinders R, Root R, Jones T, Bruce CL, Hass GM. Complement factor H-related proteins is a marker for transitional cell carcinoma of the bladder. Clinical Cancer Research 1998;4(10):2511-2520.
14. Sarosdy M, Hudson M, Ellis W, et al. Improved detection of recurrent bladder cancer using the Bard BTA stat test. J Urol 1995;154:379-384.
15. Zimmerman RL, Bagley D, Hawthorne C, Bibbo M. Utility of the Bard BTA test in detecting upper urinary tract transitional cell carcinoma. Acta Cytol 1997;41:1985.
16. Keebler CM. Cytopreparatory techniques. In: Bibbo M, editor. Comprehensive cytopathology. Second edition. Philadelphia: WB Saunders. 1997. p 906-908.